Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Hemophilia | Current Treatment: Physician Insights | US | 2018

Login to access report north_east
Contact sales account_box

Prior to the launch of Hemlibra, the hemophilia market consisted solely of factor-based products. The use of factor concentrate is highly varied; brand-dependent dosing and infusion frequencies, layered on top of patient differences and preferences, result in a complex management landscape. DRG anticipates that the next ten years will be exciting in the hemophilia space. Pipeline activity is high, and new agents offer compelling clinical profiles; however, currently available factor-based agents are entrenched, and we anticipate they will continue to experience significant uptake.

QUESTIONS ANSWERED

  • Are physicians intending to use Hemlibra prophylactically or on demand, and is this decision age-dependent? What do physicians forecast Hemlibra’s patient share will be in five years’ time?
  • What is the 2017 branded patient share of factor concentrates such as Shire’s Adynovate and CSL’s Idelvion? What are the anticipated changes in prescribing patterns once gene therapy or the aTFPI class launches?
  • Are physicians using the same brand differently for prophylaxis versus on demand?
  • How are inhibitor patients currently managed in terms of treatment strategy and brands used (e.g., NovoSeven, FEIBA)?

PRODUCT DESCRIPTION

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that clients can create specific messaging around these treatment dynamics in order to more effectively increase or defend their market position.

MARKETS COVERED

United States

PRIMARY RESEARCH INFO

Hemophilia Current Treatment: Physician Insights is a primary market research study evaluating physician self-reported prescribing and treatment practices in hemophilia. E-mail invitations were sent to hematologists to participate in an online survey. 75 hematologists completed the survey. The survey took approximately 30 minutes to complete. Fieldwork occurred in April 2018.

To qualify, respondents met the following screening criteria:

  • Board-certified in hematology.
  • In practice for a minimum of 2 years and a maximum of 35 years.
  • Do not practice in Vermont.
  • More than 75% of professional time spent in clinical practice.

After meeting the screening criteria, respondents were directed to an online survey, and respondents were paid an honorarium for their participation. Statistical significance testing was done when appropriate, including anticipated versus current allocations, subgroups, and brands.

KEY COMPANIES

Aptevo Therapeutics, Bayer HealthCare, Bioverativ, Chugai, CSL Behring, Novo Nordisk, Octapharma, Pfizer, Roche, Shire

KEY DRUGS

Advate, Adynovate, Afstyla, Alprolix, Benefix, Eloctate, FEIBA, Helixate, Hemlibra, Idelvion, Ixinity, Kogenate, Kovaltry, NovoEight, NovoSeven, Nuwiq, Rixubis, Xyntha

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Major Depressive Disorder (DSM-V) – Current Treatment – Current Treatment: Physician Insights – Major Depressive Disorder (EU5)
Across the EU5, the treatment landscape for major depressive disorder (MDD) is shaped by the widespread use of SSRIs and SNRIs, which continue to serve as firstline therapy due to their…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east